ARS Pharmaceuticals's total assets for Q4 2024 were $351.15M, an increase of 61.37% from the previous quarter. SPRY total liabilities were $94.36M for the fiscal quarter, a 467.62% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.